Long-term proton pump inhibitor use is a risk factor for mortality in patients hospitalized for COVID-19

Ahmet Yozgat Benan Kasapoglu Güray Can Alpaslan Tanoğlu Yusuf Serdar Sakin Kadir Serkan Yalçın Müjgan Gürler Mustafa Kaplan Mehmet Göktürk Kaban Mehmet Kırsoy Umut Kara Murat Kekiliİ

Published in: Turkish journal of medical sciences (2021)

The results obtained in this study show that using PPIs for more than 4 weeks is associated with negative outcomes for patients with COVID-19. Patients receiving PPI therapy should be evaluated more carefully if they are hospitalized for COVID-19 treatment.

Keyphrases

coronavirus disease
sars cov
end stage renal disease
ejection fraction
chronic kidney disease
newly diagnosed
prognostic factors
cardiovascular disease
stem cells
patient reported outcomes
skeletal muscle
respiratory syndrome coronavirus
replacement therapy
combination therapy
smoking cessation
gestational age